R&D Allosteric small molecule therapies in PD, with Gene Mack pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.
Digital FH25: Jessica DaMassa on hosting, hype, and health innovatio... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with WTF Health founder and event emcee, Jessica DaMassa
Digital Improving ROI on AI investments and data quality, with Dr Ja... Dr Jay Anders, chief medical officer for Medicomp Systems, discusses why he believes that the only way to solve AI ROI issues is to solve data quality
R&D The importance of being disruption ready, with Brandon Pence Brandon Pence, recently appointed President and COO of Fujifilm Biosciences, discusses the cell culture media industry and being disruption ready.
Market Access FH25: Commercialising Health Tech and Deeptech, with Pilar F... In a new episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida.
Digital Agentic AI, culture shifts, and commercialisation today: Ant... Hear Anthony Cilento, VP, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.